PFO
URGN icon

Pathstone Family Office’s UroGen Pharma URGN Stock Holding History

Pathstone Family Office’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-40,950
Closed -$1.47M – 709
2019
Q2 		$1.47M Buy
+40,950
New +$1.51M 0.17% 64
2019
Q1 		– Sell
-38,700
Closed -$1.67M – 950
2018
Q4 		$1.67M Buy
+38,700
New +$1.74M 0.48% 25

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pathstone Family Office's URGN Position: Q3 2019 in Review

Pathstone Family Office sold out of UroGen Pharma (URGN) in Q3 2019, closing a stake of 40,950 shares — an estimated $1.47M sold.

Pathstone Family Office first reported a position in URGN in Q4 2018 and held it in 2 quarters. The position peaked at $1.67M in Q4 2018. 84 funds tracked by Wall St. Rank hold URGN as of Q3 2019.

  • Pathstone Family Office reported no remaining UroGen Pharma position as of Q3 2019 after selling out during the quarter.
  • Pathstone Family Office sold 40,950 UroGen Pharma shares in Q3 2019, an estimated $1.47M.
  • Pathstone Family Office first reported a position in UroGen Pharma in Q4 2018 and held it in 2 quarters.
  • Pathstone Family Office's UroGen Pharma position peaked at $1.67M in Q4 2018.
  • 84 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2019.

Based on Pathstone Family Office's 13F filing for Q3 2019, filed 13 Nov 2019.